Revenue and Profitability - The company's revenue for the third quarter reached ¥196,270,919, representing a 207.25% increase year-over-year[3] - Net profit attributable to shareholders was ¥1,699,775.47, a decrease of 56.32% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was -¥835,789.50, reflecting a decline of 368.07% year-over-year[3] - The company's basic earnings per share were ¥0.0042, down 56.25% compared to the same period last year[3] - The net profit for the period was impacted by a credit impairment loss of CNY 4,555,612.37, compared to a gain of CNY 316,283.12 in the previous period[20] - The net profit for the third quarter of 2021 was CNY 3,269,778.96, a significant recovery from a net loss of CNY -3,225,437.92 in the same period last year[21] - The total comprehensive income attributable to the parent company was CNY 6,572,687.28, compared to CNY 2,284,709.88 in the previous year[22] - The company reported a total revenue of CNY 2,475,384.25 in operating profit, a turnaround from a loss of CNY -1,581,423.23 in the same quarter last year[21] - The basic and diluted earnings per share were both CNY 0.0164, compared to CNY 0.0057 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,045,633,281.48, an increase of 24.22% from the end of the previous year[3] - The total assets of the company increased to CNY 1,045,633,281.48 from CNY 841,755,807.01, reflecting a growth of about 24.2%[20] - The total liabilities rose to CNY 324,268,954.99 from CNY 137,049,500.13, indicating an increase of approximately 136.5%[19] - Total liabilities reached approximately 137.05 million, with current liabilities at 100.28 million and non-current liabilities at 36.77 million[30] - Owner's equity totaled approximately 704.71 million, with 636.05 million attributable to the parent company[30] Cash Flow and Financial Activities - The company reported a net cash flow from operating activities of -¥17,984,576.38, a significant decline of 675.24% year-to-date[3] - The net cash flow from operating activities decreased significantly to -CNY 17.98 million, a decline of 675.24% year-on-year[9] - The company experienced a 31.23% decrease in net cash flow from financing activities, amounting to CNY 21.40 million[9] - The cash flow from investment activities showed a net outflow of CNY -33,938,504.58, improving from CNY -53,007,915.95 in the previous year[25] - The company recorded a total operating cash outflow of CNY 558,243,219.88, compared to CNY 202,680,134.11 in the previous year[25] Accounts Receivable and Inventory - Accounts receivable increased by 163.66% to ¥115,797,092.54 due to increased sales activities[8] - Inventory rose by 151.54% to ¥137,521,413.85, attributed to increased stock levels at the subsidiary[8] - Accounts receivable surged to CNY 115,797,092.54, up from CNY 43,919,037.39, marking an increase of around 163.5%[18] - Inventory levels rose significantly to CNY 137,521,413.85 from CNY 54,671,128.80, which is an increase of approximately 151.1%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,866[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 41.38% of the shares, totaling 165,723,830 shares[11] Legal and Compliance Issues - The company is involved in a legal dispute regarding the validity of a share transfer contract, which may impact its operations[13] - The report for the third quarter of 2021 was not audited, indicating potential limitations in the reliability of the financial data presented[32] Research and Development - Development expenditures increased by 33.87% to ¥19,383,786.74, driven by the progress of cardiovascular generic drug LJ201801[8] - Research and development expenses decreased by 29.43% to CNY 11.55 million, indicating reduced spending on new drug development[9] Other Financial Metrics - The company confirmed a significant increase in accounts payable, which rose by 768.92% to CNY 132.75 million[9] - The company recognized a right-of-use asset and lease liability due to the new leasing standards, impacting the financial statements[31] - The company has a deferred income tax asset of approximately 7.30 million, which may provide future tax benefits[29] - The company maintained a stable capital reserve of approximately 112.77 million, reflecting consistent financial management practices[30]
龙津药业(002750) - 2021 Q3 - 季度财报